Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms

Chruściel, P. and Sahebkar, A. and Rembek-Wieliczko, M. and Serban, M. C. and Ursoniu, S. and Mikhailidis, D. P. and Jones, S. R. and Mosteoru, S. and Blaha, M. J. and Martin, S. S. and Rysz, J. and Toth, P. P. and Lip, G. Y. H. and Pencina, M. J. and Ray, K. K. and Banach, M. and Lipid, and Blood Pressure Meta-analysis Collaboration, Group (2016) Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 253. pp. 194-208.

[img] Text
1-s2.0-S0021915016311984-main (1).pdf

Download (5MB)


Background and aims The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs). Methods Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95 confidence interval (CI) as summary statistics. Results In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95 CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95 CI: −0.26, 1.65), 0.50 μg/mL (95 CI: −0.44, 1.45), −0.70 μg/mL (95 CI: −1.08, −0.33), 0.62 μg/mL (95 CI: −0.12, 1.35), and 0.51 μg/mL (95 CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95 CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95 CI: −0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95 CI: 0.01, 0.06; p = 0.002). Conclusions The meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression. © 2016 Elsevier Ireland Ltd

Item Type: Article
Additional Information: (LBPMC) Cited By :63 Export Date: 16 February 2020 CODEN: ATHSB Correspondence Address: Banach, M.; Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Poland; email:
Uncontrolled Keywords: Adiponectin Hydroxymethylglutaryl-CoA reductase inhibitors Meta-analysis Statins atorvastatin hydroxymethylglutaryl coenzyme A reductase inhibitor low density lipoprotein cholesterol pitavastatin pravastatin rosuvastatin simvastatin ADIPOQ protein, human quinoline derivative Article cholesterol blood level diabetes mellitus human meta analysis monotherapy priority journal protein blood level randomized controlled trial (topic) systematic review treatment duration treatment response adult aged blood cardiovascular disease female male middle aged regression analysis Atorvastatin Calcium Cardiovascular Diseases Humans Quinolines Randomized Controlled Trials as Topic Rosuvastatin Calcium
Subjects: WH Hemic and Lymphatic System
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib4 lib4
Date Deposited: 03 Mar 2020 05:29
Last Modified: 03 Mar 2020 05:29

Actions (login required)

View Item View Item